Skip to main content
. Author manuscript; available in PMC: 2023 Jun 15.
Published in final edited form as: Immunity. 2022 May 18;55(6):1082–1095.e5. doi: 10.1016/j.immuni.2022.04.015

Figure 4. Cysteine 151 of KEAP1 is required for NRF2 activation by indomethacin.

Figure 4.

(A) Gdf15 mRNA levels in BMDM generated from C151S KEAP1 transgenic animals and littermate controls 6 hours after stimulation with indomethacin or ketoprofen (n=4 per group). (B) NRF2 target gene expression in BMDM generated from C151S KEAP1 transgenic animals and littermate controls 6 hours after stimulation with indomethacin (n=4 per group). (C) Baseline GDF15 serum levels in C151S KEAP1 mice and controls (n=5–7 per group). (D) Plasma GDF15 levels after an intraperitoneal injection of 15 mg/kg indomethacin at the indicated time points in C151S and wildtype animals (n=5–7 per group). (E) mRNA expression of Gdf15, Hmox1, and Nqo1 at 6 hours from bulk liver of C151S and wildtype animals after treatment with 15 mg/kg indomethacin (n=4 per group). All experiments are representative and repeated at least once. Statistics by ANOVA. Data are represented as mean ± standard deviation. **P<0.01, ***P<.001, ****P<.0001